Multiple myeloma is a malignant disease that affects plasma cells, which are key elements of the immune system that produce antibodies. The pathology is characterized by abnormal division and accumulation of these cells in the bone marrow, which leads to the formation of tumor masses and disruption of normal hematopoiesis. Multiple myeloma can manifest itself in a variety of symptoms, including bone pain, anemia, increased calcium levels in the blood, and kidney dysfunction. Importantly, the disease is often associated with immunodeficiency, which increases the risk of infectious complications.
History of the disease and interesting historical facts
The history of multiple myeloma goes back to the early 20th century, when the disease was first described as a distinct entity. The first mention of multiple myeloma can be dated back to 1848, when a French physician described cases that would now be diagnosed as the disease. Since then, attention to myeloma has increased, and in 1949, the term “multiple myeloma” was first proposed. Research into the pathophysiology of myeloma has advanced significantly, especially with the introduction of new diagnostic and therapeutic technologies such as immunochemistry and chemotherapy.
Epidemiology
According to statistics, the incidence of multiple myeloma is approximately 3-4 cases per 100,000 people per year. The disease is more common in older people, with the highest incidence at the age of 65-75 years. Multiple myeloma is diagnosed in men approximately twice as often as in women. There are differences in the incidence in different ethnic groups: the greatest predisposition to myeloma is noted in African Americans, as well as in representatives of the Caucasian race, while in Asian countries the incidence rate is significantly lower.
Genetic predisposition to this disease
There are certain genetic factors that may contribute to the development of multiple myeloma. Research shows that some patients are diagnosed with mutations in the TP53, RAS, and MYC genes. These genetic changes may lead to abnormal cell division and induction of tumor progression. In addition, a predisposition to myeloma may be associated with chromosomal aberrations, such as translocations in chromosomes 14, 16, and 22, which are observed in most patients.
Risk factors for the development of this disease
There are various risk factors associated with the development of multiple myeloma, including:
- Age - The risk increases with age, especially after age 65.
- Gender - Men are more likely to develop myeloma than women.
- Ethnicity - African Americans have a higher risk.
- Occupations involving exposure to chemicals such as benzene and radiation.
- Preexisting medical conditions such as monoclonal gammopathy of undetermined significance.
Diagnosis of this disease
Diagnosis of multiple myeloma involves a comprehensive approach. The main symptoms of the disease can vary, but most often they include:
- Bone pain and loss of bone strength.
- Anemia, which manifests itself as fatigue and pale skin.
- Frequent infections due to suppression of the immune system.
- Elevated levels of calcium in the blood.
Laboratory tests are important for diagnosis and include protein, creatinine, and paraprotein levels. Radiological tests such as X-rays and MRIs are necessary to evaluate bone health and identify damage. It is also important to conduct differential diagnostics to rule out other cancers and bone diseases.
Treatment
Treatment of multiple myeloma includes both general approaches and specific methods. Initially, the first stage involves chemotherapy courses aimed at inhibiting abnormal cell division. Pharmacological treatment includes the use of agents such as bortezomib and lenalidomide. Surgery may be necessary in cases of osteolysis and spinal cord compression. Other treatment approaches include immunoprophylaxis, radiotherapy for localized cases, and high-dose chemotherapy followed by stem cell transplantation.
List of medications used to treat this disease
Medicines used to treat multiple myeloma include:
- Bortezomib (Velcade)
- Lenalidomide (Revlimid)
- Dexamethasone
- Carfilzomib (Kyprolis)
- Panobinib (Farydak)
Disease monitoring
Monitoring of patients with multiple myeloma includes regular follow-up examinations to assess paraprotein levels and kidney function. The prognosis of the disease depends on early detection and effective treatment. Complications may include infectious diseases, osteoporosis, and organ damage. Therefore, dynamic monitoring and treatment adjustments are key to maintaining the patient's condition and increasing life expectancy.
Age-related features of the disease
Age-related features of multiple myeloma have their own differences. In elderly patients, the disease is usually more aggressive and less treatable than in young patients. In young people, myeloma may have progressive dynamics associated with genetic mutations, but in general, they respond better to therapy. Moreover, the patient's age is a significant factor in choosing the appropriate treatment method and its intensity.
Questions and Answers
- What are the main symptoms of multiple myeloma? Symptoms include bone pain, anemia, high blood calcium levels, frequent infections and impaired kidney function.
- How is multiple myeloma diagnosed? Diagnosis is made using laboratory tests, radiological examination, and a bone marrow biopsy to detect abnormal cells.
- What are the risk factors for developing multiple myeloma? The main risk factors include age, gender, ethnicity, as well as previous diseases and occupational hazards.
- What treatments are available for patients with multiple myeloma? Treatment includes chemotherapy, drugs such as bortezomib and lenalidomide, radiation therapy, and the possibility of a stem cell transplant.
- How often should patients be monitored? Monitoring of the disease should be carried out regularly, usually every 2-3 months, to track the dynamics of paraproteins and identify possible complications.
